If you cannot view this message correctly, please click here.


Facebook icon




Special offer for researchers

2016 is almost over - do you still have interesting genetic projects you want to wrap up this year?
We can help you with our genome, exome, and transcriptome sequencing services.

The prices (excl. VAT) are:
  • Genome - 1,490 €
  • Exome - 390 €
  • Transcriptome for 9 samples – 2,490 €
Place your order in the next six weeks (until December 22nd 2016) to take advantage of this special offer.

Find more information on our website www.cegat.de/6weeks.

If you have any questions, please contact us at any time.


New Diagnostic Panel for Liver Diseases

CeGaT now offers a comprehensive Diagnostic Panel for hereditary childhood Liver Diseases, which has been designed in collaboration with Dr. med. Ekkehard Sturm, assistant medical director of gastroenterology at the University Children’s Hospital, Tübingen.

Childhood Liver Diseases are relatively rare disorders, and an early and precise diagnosis is of vital importance to enable an effective therapy. The use of molecular genetic analyses within these disorders offers an additional diagnostic opportunity when used in conjunction with an assessment of symptoms, laboratory, and image-guided diagnostics (Sturm und Hörtnagel, Monatszeitschrift Kinderheilkunde May 2016, Band 164, S. 448-454).

The panel comprises eight gene sets with 118 genes in total, and offers the rapid and simultaneous analysis of all disease-associated genes known to be causative for hereditary childhood Liver Diseases.

For further information please visit the page for Liver Diseases.


Massive Update and Re-organization of our Diagnostic Panel for Epilepsy, Metabolic and Brain Development Disorders

In accordance with the latest scientific findings, CeGaT has extensively updated its panel diagnostics for Epilepsy, Metabolic and Brain Development Disorders, now combining all three areas of disease on one gene panel. Our large-panel approach, unique to CeGaT, enables us to sequence all relevant 639 genes, both in parallel and in high-resolution. The new diagnostic panel is sub-divided into 28 gene-sets according to their clinical importance for the single areas of disease. With every update to the panel, currently in its 7th revision, new relevant genes are included in the analysis, reflecting the current state of scientific understanding (lately 265 genes have been included). Constantly, we adjust our technical parameters in order to increase the sequence coverage within clinically relevant areas, with the result that 99,6 % of all 639 genes are very well covered and the mean coverage of the panel is at >750x per base. This enables us to detect rare mosaic variants with high sensitivity.

In case you have any questions on how to proceed with your diagnostic analysis, or if you want to inquire regarding costs for a specific test, contact us anytime.

Please visit our webpage Epilepsy, Metabolic and Brain Development Disorders to learn more about the new Diagnostic Panel.


CeGaT wins the State Prize for young Companies




CeGaT was awarded the State Prize for young companies last night by the Baden-Württemberg regional government and the L-Bank.

Every two years the state government, in cooperation with the L-Bank, distinguishes successful Baden-Württemberg based companies which make an exemplary contribution to a future-oriented society through responsible and entrepreneurial action. The award ceremony took place at the Neues Schloss in the state capital city on Tuesday evening, where managing directors Dr. Dr. Saskia Biskup and Dr. Dirk Biskup received the award from Dr. Axel Nawrath, L-Bank chairman of the board of management. CeGaT has beaten over 603 competitors in the process of winning the award, and is the most successful young company in Baden-Württemberg.